The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol
Open accessAbstract
BACKGROUND: Short-term studies have shown that bempedoic acid, an inhibitor of ATP citrate lyase, reduces levels of low-density lipoprotein (LDL) cholesterol. Data are limited regarding the safety and efficacy of bempedoic acid treatment in long-term studies involving patients with hypercholesterolemia who are receiving guideline-recommended statin therapy. METHODS: We conducted a randomized, controlled trial involving patients with atherosclerotic cardiovascular disease, heterozygous familial hypercholesterolemia, or both. Patients had to have an LDL cholesterol level of at least 70 mg per deciliter while they were receiving maximally tolerated statin therapy with or without additional lipid-lowering therapy. (Maximally tolerated statin therapy was defined as the highest intensity statin regimen that a patient was able to maintain, as determined by the investigator.) Patients were randomly assigned in a 2:1 ratio to receive bempedoic acid or placebo. The primary end point was safety, and the principal secondary end point (principal efficacy end point) was the percentage change in the LDL cholesterol level at week 12 of 52 weeks. RESULTS: The trial involved 2230 patients, of whom 1488 were assigned to receive bempedoic acid and 742 to receive placebo. The mean (±SD) LDL cholesterol level at baseline was 103.2±29.4 mg per deciliter. The incidence of adverse events (1167 of 1487 patients [78.5%] in the bempedoic acid group and 584 of 742 [78.7%] in the placebo group) and serious adverse events (216 patients [14.5%] and 104 [14.0%], respectively) did not differ substantially between the two groups during the intervention period, but the incidence of adverse events leading to discontinuation of the regimen was higher in the bempedoic acid group than in the placebo group (162 patients [10.9%] vs. 53 [7.1%]), as was the incidence of gout (18 patients [1.2%] vs. 2 [0.3%]). At week 12, bempedoic acid reduced the mean LDL cholesterol level by 19.2 mg per deciliter, representing a change of -16.5% from baseline (difference vs. placebo in change from baseline, -18.1 percentage points; 95% confidence interval, -20.0 to -16.1; P<0.001). Safety and efficacy findings were consistent, regardless of the intensity of background statin therapy. CONCLUSIONS: In this 52-week trial, bempedoic acid added to maximally tolerated statin therapy did not lead to a higher incidence of overall adverse events than placebo and led to significantly lower LDL cholesterol levels. (Funded by Esperion Therapeutics; CLEAR Harmony ClinicalTrials.gov number, NCT02666664.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The CLEAR Harmony trial assessed bempedoic acid’s safety and efficacy in 2230 statin-treated patients with atherosclerosis or HeFH compared with placebo [130]. Relative to placebo, bempedoic acid reduced LDL-C by − 16%, non-HDL-C by − 13%, total cholesterol by − 11%, ApoB-100 by − 12% and hsCRP by − 22%.”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [130]
In the citing paper
“The incidence of adverse events was similar across both interventional groups, yet a higher percentage discounted treatment with bempedoic acid than placebo (10.9% versus 7.1%). Gout was more frequently observed among patients treated with bempedoic acid (1.2% versus 0.3%).”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [130]
In the citing paper
“Clinical trials have shown bempedoic acid reduces LDL-C levels and the CLEAR Outcomes trial demonstrated a significant reduction in MACE compared with placebo in patients who are statin intolerant [[12], [13], [14], [15],17].”
From Systematic literature review on the real-world effectiveness and safety of bempedoic acid (2026) · cites this paper as [14]
In the citing paper
“Safety findings in the real-world setting were generally aligned with those reported in RCTs and meta-analyses [[12], [13], [14], [15],17,18], although reporting was limited and inconsistently captured.”
From Systematic literature review on the real-world effectiveness and safety of bempedoic acid (2026) · cites this paper as [14]
In the citing paper
“The overall risk of bias was low 7 of 11 trials [7, 9–12, 15, 16], with 4 trials being assessed as having a moderate risk of bias [8, 13, 14, 17].”
From The Clinical Efficacy and Safety of Bempedoic Acid in Patients at Elevated Risk of Cardiovascular Disease: A Meta-Analysis of Randomized Clinical Trials (2024) · cites this paper as [12]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Enzymatic Determination of Total Serum Cholesterol
Allain, C. C., Poon, L. S., Chan, C. S. G., Richmond, W., & Fu, P. C. (1974) · Clinical Chemistry · doi:10.1093/clinchem/20.4.470 · Cited by 9,125
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437738.63853.7a · Cited by 7,081
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw272 · Cited by 3,162
Self-citationSerum triglycerides determined colorimetrically with an enzyme that produces hydrogen peroxide.
Fossati, P., & Prencipe, L. (1982) · Clinical Chemistry · doi:10.1093/clinchem/28.10.2077 · Cited by 2,905
Explaining the decrease in U.S. deaths from coronary disease, 1980–2000
Ford, E. S., Ajani, U. A., Croft, J. B., Critchley, J. A., Labarthe, D. R., Kottke, T. E., Giles, W. H., & Capewell, S. (2007) · New England Journal of Medicine · doi:10.1056/nejmsa053935 · Cited by 2,757
A peroxidase-coupled method for the colorimetric determination of serum triglycerides.
McGowan, M. W., Artiss, J. D., Strandbergh, D. R., & Zak, B. (1983) · Clinical Chemistry · doi:10.1093/clinchem/29.3.538 · Cited by 1,298
Jacobson, T. A., Ito, M. K., Maki, K. C., Orringer, C. E., Bays, H. E., Jones, P. H., McKenney, J. M., Grundy, S. M., Gill, E. A., Wild, R. A., et al. (2015) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2015.02.003 · Cited by 773
Self-citationPinkosky, S. L., Newton, R. S., Day, E. A., Ford, R. J., Lhotak, S., Austin, R. C., Birch, C. M., Smith, B. K., Filippov, S., Groot, P. H. E., et al. (2016) · Nature Communications · doi:10.1038/ncomms13457 · Cited by 498
Self-citationBallantyne, C. M., Banach, M., Mancini, G. B. J., Lepor, N. E., Hanselman, J. C., Zhao, X., & Leiter, L. A. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.06.002 · Cited by 422
Self-citationMendelian Randomization Study of ACLY and Cardiovascular Disease
Ference, B. A., Ray, K. K., Catapano, A. L., Ference, T. B., Burgess, S., Neff, D. R., Oliver-Williams, C., Wood, A. M., Butterworth, A. S., Di Angelantonio, E., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1806747 · Cited by 342
Self-citation
Cited by
Items 101–200 of 806
Minno, A. D., Lupoli, R., Calcaterra, I. L., Poggio, P., Forte, F., Spadarella, G., Ambrosino, P., Iannuzzo, G., & Minno, M. N. D. D. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.119.016262 · Cited by 73
Lipid Management in Patients Presenting With Acute Coronary Syndromes: A Review
Claessen, B. E. P. M., Guedeney, P., Gibson, C. M., Angiolillo, D. J., Cao, D., Lepor, N. E., & Mehran, R. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.120.018897 · Cited by 71
New drug approvals for 2020: Synthesis and clinical applications
Yuan, S., Luo, Y.-Q., Zuo, J.-H., Liu, H., Li, F., & Yu, B. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113284 · Cited by 64
Lalwani, N. D., Hanselman, J. C., MacDougall, D. E., Sterling, L. R., & Cramer, C. T. (2019) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2019.05.003 · Cited by 72
Self-citationLipid lowering therapy in cardiovascular disease: From myth to molecular reality
Mourikis, P., Zako, S., Dannenberg, L., Nia, A. M., Heinen, Y., Busch, L., Richter, H., Hohlfeld, T., Zeus, T., Kelm, M., et al. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107592 · Cited by 62
Changes in Cells Associated with Insulin Resistance
Szablewski, L. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25042397 · Cited by 88
“Other drugs may be used, such as insulin-like growth factor-1 in the case of patients with Donohue syndrome [238], insulin sensitizers such as metformin and thiazolidinediones in the case of patients with lipodystrophies [239] and lipid-lowering medications [240].”
MethodBalla, S., Ekpo, E., Wilemon, K. A., Knowles, J. W., & Rodríguez, F. (2020) · Current Atherosclerosis Reports · doi:10.1007/s11883-020-00881-5 · Cited by 65
Beyond statins: New pharmacological targets to decrease LDL-cholesterol and cardiovascular events
Raschi, E., Casula, M., Cicero, A. F. G., Corsini, A., Borghi, C., & Catapano, A. L. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108507 · Cited by 71
Self-citationWang, X., Zhang, Y., Tan, H., Wang, P., Zha, X., Chong, W., Zhou, L., & Fang, F. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01101-9 · Cited by 68
Antisense Oligonucleotides and Small Interfering RNA for the Treatment of Dyslipidemias
Gareri, C., Polimeni, A., Giordano, S. A., Tammè, L., Curcio, A., & Indolfi, C. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11133884 · Cited by 64
“Recent studies showed it to be effective and safe in combination with statins for lowering LDL-C, and it has the potential to reduce the risk of musclerelated adverse events, which can limit the utilization and effectiveness of statin therapy [3].”
BackgroundMolecular basis for acetyl-CoA production by ATP-citrate lyase
Wei, X., Schultz, K. C., Bazilevsky, G. A., Vogt, A. D., & Marmorstein, R. (2019) · Nature Structural & Molecular Biology · doi:10.1038/s41594-019-0351-6 · Cited by 59
Swerdlow, D. I., Rider, D. A., Yavari, A., Lindholm, M., Campion, G., & Nissen, S. E. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvab100 · Cited by 62
New Therapies for Primary Hyperlipidemia
Aguilar-Salinas, C. A., Gómez-Díaz, R. A., & Corral, P. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab876 · Cited by 67
Klug, E. Q., Llerena, S., Burgess, L. J., Fourie, N., Scott, R. S., Vest, J., Caldwell, K., Kallend, D. G., Stein, E. A., & LIBERATE-HR Investigators (2024) · JAMA Cardiology · doi:10.1001/jamacardio.2024.1659 · Cited by 67
Mach, F., Visseren, F. L. J., Cater, N. B., Salhi, N., Soronen, J., Ray, K. K., Delgado, V., Jukema, J. W., Laufs, U., Zamorano, J.-L., et al. (2024) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2024.07.001 · Cited by 57
Self-citationA Placebo-Controlled Trial of the Oral PCSK9 Inhibitor Enlicitide
Navar, A. M., Mikhailova, E., Catapano, A. L., Banka, P., Blom, D. J., Cadena, A., Kourpanidis, S., Lepor, N. E., Tsukamoto, K., Mendizabal, G., et al. (2026) · New England Journal of Medicine · doi:10.1056/nejmoa2511002 · Cited by 57
Self-citationToth, P. P., Bray, S., Villa, G., Palagashvili, T., Sattar, N., Stroes, E. S. G., & Worth, G. M. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.122.025551 · Cited by 56
“18,45,59 CONCLUSIONS All nonstatin agents significantly reduced LDL-C levels compared with placebo.”
Advances in treatment of Dyslipidemia
Dybiec, J., Baran, W., Dąbek, B., Fularski, P., Młynarska, E., Radzioch, E., Rysz, J., & Franczyk, B. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241713288 · Cited by 55
Gargiulo, P., Basile, C., Cesaro, A., Marzano, F., Buonocore, D., Asile, G., Abbate, V., Vicidomini, F., Paolillo, S., Spaccarotella, C., et al. (2023) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2023.01.001 · Cited by 61
New Trends in Dyslipidemia Treatment
Jang, A. Y., Lim, S., Jo, S.-H., Han, S. H., & Koh, K. K. (2020) · Circulation Journal · doi:10.1253/circj.cj-20-1037 · Cited by 62
Masana, L., Ibarretxe, D., & Plana, N. (2020) · Current Cardiology Reports · doi:10.1007/s11886-020-01326-w · Cited by 61
Novel Therapeutical Approaches to Managing Atherosclerotic Risk
Giglio, R. V., Stoian, A. P., Al‐Rasadi, K., Banach, M., Patti, A. M., Ciaccio, M., Rizvi, A. A., & Rizzo, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094633 · Cited by 57
Xiong, J., Zhou, P., Jiang, H., Huang, T., He, Y., Zhao, Z., Zang, Y., Choo, Y., Wang, X., Chittiboyina, A. G., et al. (2021) · Angewandte Chemie International Edition · doi:10.1002/anie.202109082 · Cited by 54
Contemporary Management of Dyslipidemia
Ferraro, R., Leucker, T. M., Martin, S. S., Banach, M., Jones, S. R., & Toth, P. P. (2022) · Drugs · doi:10.1007/s40265-022-01691-6 · Cited by 66
Management of Familial Hypercholesterolemia: Current Status and Future Perspectives
Lui, D. T. W., Lee, A. C. H., & Tan, K. C. B. (2020) · Journal of the Endocrine Society · doi:10.1210/jendso/bvaa122 · Cited by 68
“In hypercholesterolemic patients already receiving guideline-recommended statin therapy, bempedoic acid 180 mg daily further reduced LDL-C levels by 17% (Cholesterol Lowering via Bempedoic Acid and ACL-Inhibiting Regimen [CLEAR] Harmony trial) [116], and the CLEAR Wisdom trial confirmed a similar efficacy of bempedoic…”
InfluentialBallantyne, C. M., Banach, M., Bays, H. E., Catapano, A. L., Laufs, U., Stroes, E. S. G., Robinson, P. L., Lei, L., & Ray, K. K. (2022) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2022.03.020 · Cited by 58
Self-citationFreeman, A., Raman, S., Aggarwal, M., Maron, D., Bhatt, D. L., Parwani, P. J., Osborne, J., Earls, J., Min, J., & Shapiro, M. (2022) · American Journal of Medicine · doi:10.1016/j.amjmed.2022.10.021 · Cited by 44
ROS-Induced Endothelial Dysfunction in the Pathogenesis of Atherosclerosis
Yan, R., Zhang, X., Xu, W., Li, J., Sun, Y., Cui, S., Xu, R., Li, W., Jiao, L., & Wang, T. (2024) · Aging and Disease · doi:10.14336/ad.2024.0309 · Cited by 118
Current Options and Future Perspectives in the Treatment of Dyslipidemia
Muscoli, S., Ifrim, M., Russo, M., Candido, F., Sanseviero, A., Milite, M., Luozzo, M. D., Marchei, M., & Sangiorgi, G. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11164716 · Cited by 56
“However, BA led to a higher incidence of ADEs leading to discontinuation and gout [34].”
BackgroundCicero, A. F. G., Pontremoli, R., Fogacci, F., Viazzi, F. C., & Borghi, C. (2020) · Drug Safety · doi:10.1007/s40264-020-00931-6 · Cited by 55
Acetyl-CoA and Metabolite Fluxes Regulate White Adipose Tissue Expansion
Felix, J. B., Cox, A. R., & Hartig, S. M. (2021) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2021.02.008 · Cited by 61
Bempedoic acid and its role in contemporary management of hyperlipidemia in atherosclerosis
Tummala, R., Gupta, M., Devanabanda, A. R., Bandyopadhyay, D., Aronow, W. S., Ray, K. K., Mamas, M. A., & Ghosh, R. K. (2022) · Annals of Medicine · doi:10.1080/07853890.2022.2059559 · Cited by 56
“was under-powered to specifically study this effect [42].”
BackgroundSelf-citationTaylor, H. E., Calantone, N., Lichon, D., Hudson, H., Clerc, I., Campbell, E. M., & D’Aquila, R. T. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107810 · Cited by 54
Berman, A. N., & Blankstein, R. (2019) · Current Cardiology Reports · doi:10.1007/s11886-019-1175-z · Cited by 55
Clinical Pharmacology of Statins: an Update
Ferri, N., & Corsini, A. (2020) · Current Atherosclerosis Reports · doi:10.1007/s11883-020-00844-w · Cited by 56
Agrawal, H., Choy, H.-H., Liu, J., Auyoung, M., & Albert, M. A. (2020) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.120.313608 · Cited by 62
Risk Factors and Cardiovascular Disease in the Elderly
Díez‐Villanueva, P., Jiménez-Méndez, C., Bonanad, C., García‐Blas, S., Pérez-Rivera, J.-Á., Miguel, G. A., García‐Pardo, H., Formiga, F., Camafort, M., Martínez‐Sellés, M., et al. (2022) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2306188 · Cited by 60
“Both drugs have showed to provide a safe and effective reduction in LDL levels in patients over 65 and 75 years of age, similar to their younger counterparts [55,56].”
BackgroundWellen, K. E., & Snyder, N. W. (2019) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0000000000000580 · Cited by 54
“Cytosolic acetylCoA production is nowa validated therapeutic target, with a positive phase III trial for lowering LDL-cholesterol by the ACLY inhibitor bempedoic acid [6].”
BackgroundPercutaneous Coronary Revascularization
Serruys, P. W. J. C., Ono, M., Garg, S., Hara, H., Kawashima, H., Pompilio, G., Andreini, D., Holmes, D. R., Onuma, Y., & King, S. B. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.05.024 · Cited by 48
Emerging roles of fatty acid metabolism in cancer and their targeted drug development
An, Q., Lin, R., Wang, D., & Wang, C. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114613 · Cited by 47
Development of the novel ACLY inhibitor 326E as a promising treatment for hypercholesterolemia
Xie, Z., Zhang, M., Song, Q., Cheng, L., Zhang, X., Song, G., Sun, X., Gu, M., Zhou, C., Zhang, Y., et al. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.06.011 · Cited by 46
De Filippo, O., D’Ascenzo, F., Iannaccone, M., Bertaina, M., Leone, A., Borzillo, I., Ravetti, E., Solano, A., Pagliassotto, I., Nebiolo, M., et al. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-02022-z · Cited by 43
“…enrolled statin-intolerant patients [12, 15, 17, 21, 22], 2 studies enrolled patients with ASCVD and/or FH on stable statin background therapy [13, 14], one multi-arm trial included patients with ASCVD and/or FH and/or multiple CV risk factors [23], 3 trials enrolled patients with…”
BackgroundThe effect of CETP inhibitors on new-onset diabetes: a systematic review and meta-analysis
Dangas, K., Navar, A.-M., & Kastelein, J. J. P. (2022) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvac025 · Cited by 48
Unraveling the intricate relationship between lipid metabolism and oncogenic signaling pathways
Khan, F., Elsori, D. H., Verma, M., Pandey, S., Rab, S. O., Siddiqui, S., Alabdallah, N. M., Saeed, M., & Pandey, P. (2024) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1399065 · Cited by 53
“Due to its crucial involvement in lipid production, ACLY inhibitors, initially designed for metabolic conditions like hypercholesterolemia and type 2 diabetes, are now being explored as potential treatments for cancer (Granchi, 2018; Ray et al., 2019).”
BackgroundSakuma, I., Gaspar, R. C., Nasiri, A. R., Dufour, S., Kahn, M., Zheng, J., LaMoia, T. E., Guerra, M. T., Taki, Y., Kawashima, Y., et al. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2502978122 · Cited by 46
“Bempedoic acid works as an ATP - citrate lyase inhibitor, which is clinically used as a plasma cholesterol - lowering drug (21).”
Low-Density Lipoprotein Cholesterol-Lowering Drugs: A Narrative Review
Ferri, N., Ruscica, M., Fazio, S., & Corsini, A. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13040943 · Cited by 51
“Data from phase 3 studies showed an increase in serum uric acid and creatinine levels in patients treated with bempedoic acid [129].”
An update on pharmacotherapies in diabetic dyslipidemia
Gupta, M., Tummala, R., Ghosh, R. K., Blumenthal, C., Philip, K., Bandyopadhyay, D., Ventura, H. O., & DEEDWANIA, P. C. (2019) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2019.07.006 · Cited by 43
Dai, L., Zuo, Y., You, Q., Zeng, H., & Cao, S. (2020) · European Journal of Preventive Cardiology · doi:10.1177/2047487320930585 · Cited by 44
Colesterol LDL y aterosclerosis: evidencias
Guijarro, C., & Cosín-Sales, J. (2021) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2020.12.004 · Cited by 67
Efficacy and safety of bempedoic acid in patients not receiving statins in phase 3 clinical trials
Laufs, U., Ballantyne, C. M., Banach, M., Bays, H. E., Catapano, A. L., Duell, P. B., Goldberg, A. C., Gotto, A. M., Leiter, L. A., Ray, K. K., et al. (2022) · Journal of clinical lipidology · doi:10.1016/j.jacl.2022.03.001 · Cited by 45
Self-citationLp(a): a New Pathway to Target?
Nurmohamed, N. S., Kraaijenhof, J. M., & Stroes, E. S. G. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01060-4 · Cited by 48
Jin, F., Li, J., Guo, J., Doeppner, T. R., Hermann, D. M., Yao, G., & Dai, Y. (2021) · European Heart Journal Open · doi:10.1093/ehjopen/oeab022 · Cited by 41
“…approaches seem also promising, including bempedoic acid (an adenosine triphosphate-citrate lyase inhibitor that reduces cholesterol synthesis), 39 pemafibrate (a PPAR a modulator), 40 evinacumab (a monoclonal antibody against ANGPTL3 that inhibits lipoprotein lipase, an enzyme involved in the…”
BackgroundNovel and Emerging LDL-C Lowering Strategies: A New Era of Dyslipidemia Management
Agnello, F., Ingala, S., Laterra, G., Scalia, L., & Barbanti, M. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13051251 · Cited by 39
“Indeed, compared with placebo, the combination of bempedoic acid with moderate or high-intensity statin produced a greater reduction in LDL-C levels [34].”
BackgroundJiang, Y., Wu, L., Zhu, X., Bian, H., Gao, X., & Xia, M. (2024) · Lipids in Health and Disease · doi:10.1186/s12944-024-02092-2 · Cited by 50
“Clinical trials have showed positive outcomes on reduction of low-density lipoprotein (LDL) levels and cardiovascular risk [66, 67], while the efficacy among patients with MASLD remains to be studied.”
BackgroundInsights into incretin-based therapies for treatment of diabetic dyslipidemia
Stemmer, K., Finan, B., DiMarchi, R. D., Tschöp, M. H., & Müller, T. D. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.05.008 · Cited by 43
“Patients that do not achieve their LDL-C treatment goals despite high doses of statins may further be subjected to LDL-lowering add on therapies such as the ATP citrate lyase bempedoic acid [11,12], inhibitors of intestinal cholesterol absorption (ezetimibe) [13], or inhibitors of proprotein convertase subtilisin kexi…”
BackgroundReal-world utilization of bempedoic acid in an academic preventive cardiology practice
Warden, B. A., Cardiology, B.-A., Purnell, J. Q., Duell, P. B., & Fazio, S. (2022) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2021.11.013 · Cited by 39
Lin, Y., Parco, C., Karathanos, A., Krieger, T., Schulze, V., Chernyak, N., Icks, A., Kelm, M., Brockmeyer, M., & Wolff, G. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-048893 · Cited by 38
Raygor, V., & Khera, A. (2020) · Current Cardiology Reports · doi:10.1007/s11886-020-01331-z · Cited by 39
Role of Vitamin B12 and Folate in Metabolic Syndrome
Ashok, T., Puttam, H., Tarnate, V. C. A., Jhaveri, S., Avanthika, C., Treviño, A. G. T., Sandeep, S. L., & Ahmed, N. (2021) · Cureus · doi:10.7759/cureus.18521 · Cited by 53
“The most frequent adverse effects observed included nasopharyngitis, muscle spasms, hyperuricemia, anemia, and elevated transaminases [177,178].”
BackgroundProgress of potential drugs targeted in lipid metabolism research
Liang, K., & Dai, J. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1067652 · Cited by 38
Chinese expert consensus on blood lipid management in patients with diabetes (2024 edition)
Xiao, Y., Yu, B., Chen, C., Wang, S., Hu, D., Wu, C., Luo, Y., Xie, L., Li, C., Peng, D., et al. (2024) · Journal of Translational Internal Medicine · doi:10.2478/jtim-2024-0014 · Cited by 41
“[103,104] The CLEAR-Outcomes study confirmed that bempedoic acid can reduce the risk of MACE with overall good safety and tolerability without leading to related myopathy, abnormal blood glucose, or other adverse reactions.”
Bempedoic acid for the treatment of dyslipidemia
Marrs, J. C., & Anderson, S. L. (2020) · Drugs in Context · doi:10.7573/dic.2020-6-5 · Cited by 44
Comparative Cardiovascular Benefits of Bempedoic Acid and Statin Drugs
Lincoff, A. M., Ray, K. K., Sasiela, W. J., Haddad, T. M., Nicholls, S. J., Li, N., Cho, L., Mason, D., Libby, P., Goodman, S. G., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.04.048 · Cited by 48
Self-citationA Review of the Efficacy and Tolerability of Bempedoic Acid in the Treatment of Hypercholesterolemia
Niman, S., Rana, K., Reid, J., Sheikh‐Ali, M., Lewis, T., Choksi, R. R., & Goldfaden, R. F. (2020) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-020-00399-w · Cited by 37
“This lipid-lowering effect was maintained at week 24, with an LDL-C lowering of − 16.1% from baseline, and was seen through the 52 weeks of treatment even with the varying intensity of other LLT [39].”
InfluentialJadhav, S. B., Crass, R. L., Chapel, S. H., Kerschnitzki, M., Sasiela, W. J., Emery, M. G., Amore, B. M., Barrett, P. H. R., Watts, G. F., & Catapano, A. L. (2021) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvab064 · Cited by 40
Self-citationBanach, M., Burchardt, P., Chlebus, K., Dobrowolski, P., Dudek, D., Dyrbuś, K., Gąsior, M., Jankowski, P., Jozwiak, J. J., Kłosiewicz−Latoszek, L., et al. (2021) · Diagnostyka Laboratoryjna · doi:10.5604/01.3001.0015.4805 · Cited by 36
Lowering low-density lipoprotein cholesterol: from mechanisms to therapies
Luo, J., Wang, J.-K., & Song, B. (2022) · Life Metabolism · doi:10.1093/lifemeta/loac004 · Cited by 41
New Therapeutic Approaches in Treatment of Dyslipidaemia—A Narrative Review
Merćep, I., Strikić, D., Slišković, A. M., & Reiner, Ž. (2022) · Pharmaceuticals · doi:10.3390/ph15070839 · Cited by 39
“1% reductions in LDL cholesterol levels in the blood respectively, after 12 weeks of therapy [33,34].”
BackgroundNuclear receptors, cholesterol homeostasis and the immune system
Shahoei, S. H., & Nelson, E. R. (2019) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2019.04.013 · Cited by 43
Lipid lowering for prevention of venous thromboembolism: a network meta-analysis
Farmakis, I. T., Christodoulou, K. C., Hobohm, L., Konstantinides, S., & Valerio, L. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae361 · Cited by 36
Adenosine Triphosphate Citrate Lyase and Fatty Acid Synthesis Inhibition: A Narrative Review
Lau, F. D., & Giugliano, R. P. (2023) · JAMA Cardiology · doi:10.1001/jamacardio.2023.2402 · Cited by 41
Effect of bempedoic acid on new onset or worsening diabetes: a meta-analysis
Masson, W., Lobo, M., Lavalle-Cobo, A., Masson, G., & Molinero, G. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108369 · Cited by 34
Lipid-Lowering Drug Therapy: Critical Approach for Implementation in Clinical Practice
Rossi, M., Fabris, E., Barbisan, D., Massa, L., & Sinagra, G. (2021) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-021-00497-3 · Cited by 36
Yenilmez, B., Kelly, M., Zhang, G., Wetoska, N., Ilkayeva, O., Min, K., Rowland, L. A., DiMarzio, C., He, W., Raymond, N., et al. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.102401 · Cited by 37
“In phase 3 clinical trials, bempedoic acid reduced the mean low-density lipoprotein cholesterol level by up to 30% (81) in patients with hypercholesterolemia and by around 18% in patients on statin medications (80).”
BackgroundRecent advances in synthetic pharmacotherapies for dyslipidaemias
Sirtori, C. R., Yamashita, S., Greco, M. F., Corsini, A., Watts, G. F., & Ruscica, M. (2019) · European Journal of Preventive Cardiology · doi:10.1177/2047487319845314 · Cited by 34
“4% (week 52) over placebo.(40) The CLEARWisdom trial evaluated the efficacy and safety of bempedoic acid in patients with pre-existing ASCVD risk and/or HeFH, already at maximally tolerated statin doses and requiring additional LDL-C lowering.”
Desjardins, E. M., Wu, J., Lavoie, D. C. T., Ahmadi, E., Townsend, L. K., Morrow, M. R., Wang, D., Tsakiridis, E. E., Batchuluun, B., Fayyazi, R., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101193 · Cited by 33
Brandts, J., & Ray, K. K. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1778668 · Cited by 33
Self-citationNovel Lipid-Lowering Therapies to Reduce Cardiovascular Risk
Wilkins, J. T., & Lloyd‐Jones, D. M. (2021) · JAMA · doi:10.1001/jama.2021.2244 · Cited by 33
Pharmacokinetics of bempedoic acid in patients with renal impairment
Amore, B. M., Sasiela, W. J., Ries, D. K., Tresh, P., & Emery, M. G. (2021) · Clinical and Translational Science · doi:10.1111/cts.13202 · Cited by 34
Srivastava, R. A. K. (2023) · Cells · doi:10.3390/cells12121648 · Cited by 48
“Nexletol LDL lowering LDL ACLY Inhibitor [42,44]”
BackgroundWang, Y., Han, S., Qin, H., Zheng, H., Jiang, B., Cao, Y., Gao, Y., Guan, L., Jia, Q., Jiang, Y., et al. (2020) · Stroke and Vascular Neurology · doi:10.1136/svn-2020-000385 · Cited by 32
Emerging agents for the treatment and prevention of stroke: progress in clinical trials
Safouris, A., Magoufis, G., & Tsivgoulis, G. K. (2021) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2021.1985463 · Cited by 32
“The CLEAR Wisdom and CLEAR Harmony trials tested the addition of bempedoic acid on top of maximally tolerated statin therapy in high-risk individuals and found significant LDL-C reduction [75,76].”
MethodBrandts, J., Tittel, S. R., Bramlage, P., Danne, T., Brix, J. M., Zimny, S., Heyer, C. H. J., Holl, R. W., & Müller‐Wieland, D. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15264 · Cited by 31
Potential therapeutic strategies for MASH: from preclinical to clinical development
Xie, Z., Li, Y., Cheng, L., Huang, Y., Rao, W., Shi, H., & Li, J. (2024) · Life Metabolism · doi:10.1093/lifemeta/loae029 · Cited by 32
Galli, M., Abbate, A., Bonaca, M. P., Crea, F., Forte, M., Frati, G., Gaudino, M. F. L., Gibson, C. M., Gorog, D. A., Mehran, R., et al. (2026) · Nature Reviews Cardiology · doi:10.1038/s41569-026-01249-z · Cited by 49
“However, bempedoic acid reduced plasma apoB levels in patients with hypercholesterolaemia taking statins 273,274 and sd-LDL and non-HDL-cholesterol levels in patients with intolerance to statins 275,276 compared with placebo.”
Treating Coronary Artery Disease: Beyond Statins, Ezetimibe, and PCSK9 Inhibition
Musunuru, K. (2020) · Annual Review of Medicine · doi:10.1146/annurev-med-080819-044918 · Cited by 34
Dyslipidemia and prevention of atherosclerotic cardiovascular disease in the elderly
LUCCHI, T. (2022) · Minerva Medica · doi:10.23736/s0026-4806.21.07347-x · Cited by 41
Volpe, M., Gallo, G., Modena, M. G., Ferri, C., Desideri, G., Tocci, G., Members of the Board of the Italian Society of Cardiovascular Prevention, Bellone, S., Bertolotti, M., Biffi, A., et al. (2022) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-021-00503-4 · Cited by 35
Maierean, S. M., Webb, R. J., Banach, M., & Mazidi, M. (2022) · European Heart Journal Open · doi:10.1093/ehjopen/oeac039 · Cited by 37
“Safety and efficacy findings were consistent, regardless of the intensity of background statin therapy.(91) As far as the authors are”
BackgroundTreatment of dyslipidemia in kidney transplantation
Ponticelli, C. E., Arnaboldi, L., Moroni, G. L., & Corsini, A. (2020) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2020.1732921 · Cited by 32
New and emerging lipid-modifying drugs to lower LDL cholesterol
Kosmas, C. E., Pantou, D., Sourlas, A., Papakonstantinou, E. J., Uceta, R. E., & Guzman, E. (2021) · Drugs in Context · doi:10.7573/dic.2021-8-3 · Cited by 35
Forrestiacids C and D, unprecedented triterpene-diterpene adducts from Pseudotsuga forrestii
Zhou, P., Zang, Y., Li, C., Yuan, L., Zeng, H., Li, J. X., Hu, J., & Xiong, J. (2021) · Chinese Chemical Letters · doi:10.1016/j.cclet.2021.12.009 · Cited by 29
Safety of Statins and Nonstatins for Treatment of Dyslipidemia
Newman, C. B. (2022) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2022.01.004 · Cited by 39
Statin associated muscle symptoms: An update and review
Dicken, W., Mehta, A., Karagiannis, A. D., Jain, V., Vavuranakis, M., Sperling, L. S., & Cassimatis, D. C. (2022) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2022.11.010 · Cited by 31
Combined inhibition of ACLY and CDK4/6 reduces cancer cell growth and invasion
Velez, B. C., Petrella, C., DiSalvo, K. H., Cheng, K., Kravtsov, R. L., Krasniqi, D., & Krucher, N. A. (2022) · Oncology Reports · doi:10.3892/or.2022.8469 · Cited by 36
Human Genetics and Drug Development
Holmes, M. V. (2019) · New England Journal of Medicine · doi:10.1056/nejme1901565 · Cited by 28
Luo, Y., & Peng, D. (2023) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/10742484231189597 · Cited by 32
Parhofer, K. G., Aguíar, C., Banach, M., Drexel, H., Gouni‐Berthold, I., de Isla, L. P., Rietzschel, E. R., Zambon, A., & Ray, K. K. (2025) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvaf007 · Cited by 34
“60 –63 In clinical trials, bempedoic acid showed a good safety profile, with an incidence of muscular and serious adverse events comparable to placebo.”
Self-citationLipid-lowering agents for concurrent cardiovascular and chronic kidney disease
Katsiki, N., Mikhailidis, D. P., & Banach, M. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1649394 · Cited by 28
“1%) were higher in the bempedoic acid compared with the placebo group [153].”
BackgroundMethodLandscape of Statin as a Cornerstone in Atherosclerotic Cardiovascular Disease
Yang, C., Wu, Y., Qian, J., & Li, J. (2023) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2412373 · Cited by 30
Metadata
- Authors
- Ray, K. K., Bays, H. E., Catapano, A. L., Lalwani, N. D., Bloedon, L. T., Sterling, L. R., Robinson, P. L., & Ballantyne, C. M.
- Affiliations
- Baylor College of Medicine (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-03-14
- Volume
- 380
- Issue
- 11
- Pages
- 1022-1032
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2922038538
- Cited by
- 807
- References
- 20
- Citations by year
- 2026: 77 · 2025: 87 · 2024: 114 · 2023: 143 · 2022: 116 · 2021: 107 · 2020: 107 · 2019: 53
- FWCI
- 91.62
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Spiral (Imperial College London) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Keywords
- bempedoic acid, LDL cholesterol lowering, ATP-citrate lyase inhibitor, hypercholesterolemia, atherosclerotic cardiovascular disease, heterozygous familial hypercholesterolemia, statin therapy, gout, adverse events, drug safety, lipid-lowering therapy, long-term treatment, gout risk, statin intolerance
- MeSH terms
- Aged, Apolipoproteins B, ATP Citrate (pro-S)-Lyase, C-Reactive Protein, Cholesterol, Dicarboxylic Acids, Drug Therapy, Combination, Fatty Acids, Female, Humans, Hypercholesterolemia, Hypoglycemic Agents, Cholesterol, LDL, Male, Middle Aged, Peptide Fragments, Treatment Outcome, Hydroxymethylglutaryl-CoA Reductase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.